Abstract:Background: The gut–liver axis plays a crucial role in various liver diseases. Therefore, targeting this crosstalk may provide a new treatment strategy for liver diseases. However, the exact mechanism underlying this crosstalk and its impact on drug-induced liver injury (DILI) requires clarification. Aim: This study aimed to investigate the potential mechanism and therapeutic effect of MgIG on MTX-induced liver injury, which is associated with the gut–liver axis and gut microbiota. Methods: An MTX-induced liver injury model was generated after 20-mg/kg/3d MTX application for 30 days. Meanwhile, the treatment group was treated with 40-mg/kg MgIG daily. Histological examination, aminotransferase, and aspartate aminotransferase enzyme levels were estimated to evaluate liver function. Immune cells infiltration and inflammatory cytokines were detected to indicate inflammation levels. Colon histological score, intestinal barrier leakage, and expression of tight junctions were employed to assess the intestinal injury. Bacterial translocation was observed using fluorescent in situ hybridisation, colony-forming unit counting, and lipopolysaccharide detection. Alterations in gut microbial composition were analysed using 16s rDNA sequencing and relative quantitative polymerase chain reaction. Short-chain-fatty-acids and lactic acid concentrations were then utilized to validate changes in metabolites of specific bacteria. Lactobacillus sp. supplement and fecal microbiota transplantation were used to evaluate gut microbiota contribution. Results: MTX-induced intestinal and liver injuries were significantly alleviated using MgIG treatment. Bacterial translocation resulting from the intestinal barrier disruption was considered a crucial cause of MTX-induced liver injury and the therapeutic target of MgIG. Moreover, MgIG was speculated to have changed the gut microbial composition by up-regulating probiotic Lactobacillus and down-regulating Muribaculaceae , thereby remodelling the intestinal barrier and inhibiting bacterial translocation. Conclusion: The MTX-induced intestinal barrier was protected owing to MgIG administration, which reshaped the gut microbial composition and inhibited bacterial translocation into the liver, thus attenuating MTX-related DILI.

Mg and the microbiome: A liver-protective duo

The Gut Microbiome and Intestinal Failure-Associated Liver Disease

Oral magnesium prevents acetaminophen-induced acute liver injury by modulating microbial metabolism

Microbial Infections As A Trigger For Acute-Onchronic Liver Failure: A Review

Lactobacillus Helveticus R0052 Alleviates Liver Injury by Modulating Gut Microbiome and Metabolome in D-galactosamine-treated Rats.

Infectious Microecology in Liver Disease

Modulation of Gut Microbiota by Magnesium Isoglycyrrhizinate Mediates Enhancement of Intestinal Barrier Function and Amelioration of Methotrexate-Induced Liver Injury

Effects of gut microflora on hepatic damage after acute liver injury in rats.

Protective Effect of Lactobacillus Salivarius Li01 on Thioacetamide‐induced Acute Liver Injury and Hyperammonaemia

Bifidobacterium adolescentis CGMCC 15058 alleviates liver injury, enhances the intestinal barrier and modifies the gut microbiota in d -galactosamine-treated rats

Amelioration of Ethanol-Induced Hepatitis by Magnesium Isoglycyrrhizinate Through Inhibition of Neutrophil Cell Infiltration and Oxidative Damage.

Magnesium Isoglycyrrhizinate Attenuates D-galactosamine/lipopolysaccharides Induced Acute Liver Injury of Rat Via Regulation of the P38-Mapk and NF-κB Signaling Pathways

Protective effect of<i>Lactobacillus salivarius</i>Li01 on thioacetamide-induced acute liver injury and hyperammonaemia

<i>Bifidobacterium longum</i> R0175 Protects Rats against D-Galactosamine-Induced Acute Liver Failure

Functional Assessment of MGO Nanoparticle Supplementation in an Acute Liver Injury Rat Model

Magnesium Isoglycyrrhizinate Ameliorates Concanavalin A-Induced Liver Injury by Inhibiting Autophagy

<i>Akkermansia muciniphila</i> Ameliorates Acetaminophen-Induced Liver Injury by Regulating Gut Microbial Composition and Metabolism

Gut microbiota-derived glutamine attenuates liver ischemia/reperfusion injury via macrophage metabolic reprogramming

Magnesium isoglycyrrhizinate ameliorates concanavalin A-induced liver injury via the p38 and JNK MAPK pathway

Magnesium Lithospermate B Reduces Inflammatory Response in a Mouse Model of Hepatic Ischemia–Reperfusion Injury

Integrating Metabolomics and Network Pharmacology to Decipher the Hepatoprotective Effect Mechanisms of Magnesium Isoglycyrrhizinate Injection